|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date27 Jun 2018 |
|
MechanismEGFR exon 20 inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A multi-center retrospective study of neratinib as extended adjuvant therapy to describe patient characteristics, treatment patterns, safety, and effectiveness in HER2-positive early breast cancer patients in China
/ RecruitingNot ApplicableIIT A Retrospective-Prospective observational study in China to describe the management in clinical practice of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation who have received prior systemic therapy
100 Clinical Results associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.
0 Patents (Medical) associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.
100 Deals associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.
100 Translational Medicine associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.